Tissue engineered small-diameter vascular grafts
Tissue engineered small-diameter vascular grafts
复制标题
DOI：
10.1016/s0094-1298(03)00069-5
复制
发表时间：
2003-10-01
影响因子：
2.3
通讯作者：
West, JL
中科院分区：
文献类型：
--
作者：
Schmedlen, RH;Elbjeirami, WM;West, JL
超过6000万美国人患有某种心血管疾病。结果往往是致命的：心血管疾病(CVD)导致了美国大多数人的死亡。心血管疾病每年夺走的生命比排在其后的五大死因加起来还要多[1]。2000年，每五名美国人中就有一人死于冠心病，这是一种小血管疾病，需要接受大约500,000例冠状动脉搭桥术(CABG)。旁路移植在治疗动脉瘤性疾病或创伤时也可能被认为是必要的。目前，外科医生使用自体组织和合成生物材料作为血管移植物进行这些手术。尽管对血管移植物的需求很大，但这些材料对于小直径血管(内径)来说供不应求或缺乏长期通畅性
Over 60 million Americans suffer from some type of cardiovascular disorder. The outcome is often fatal: Cardiovascular diseases (CVDs) result in the majority of deaths in the United States. CVD claims more lives each year than the next five leading causes of death combined [1]. Coronary heart disease, an affliction of a small-diameter blood vessel, caused more than one in every five American deaths in 2000 and required approximately 500,000 coronary artery bypass graft surgeries (CABGs). Bypass grafting may also be considered necessary in the treatment of aneurysmal disease or trauma. At present, surgeons use autologous tissue and synthetic biomaterials as vascular grafts for these procedures. Despite the large demand for vascular grafts, these materials exist in short supply or lack long-term patency for small-diameter vessels (inner diameter